The University of Southampton
University of Southampton Institutional Repository

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response
Follicular lymphoma (FL) cells express CD20 and are associated in most cases with the t(14;18) chromosomal translocation. A multicentre study was undertaken between January 1997 and January 1998 to assess the complete response rate (CR) and overall response rate (RR) to rituximab, a chimaeric anti-CD20 monoclonal antibody. Seventy patients with previously treated FL received rituximab (375 mg/m2/week x4, by intravenous infusion). Restaging studies were performed 1 and 2 months after therapy. Molecular monitoring for the presence of cells harbouring the Bcl-2/JH gene rearrangement in the peripheral blood (PB) and bone marrow (BM) was performed before and after treatment using a two-step semi-nested polymerase chain reaction (PCR) assay. The overall RR was 32/70 (46%), being highest in patients who had received only one previous treatment (12/15, 80%). However, only two patients achieved a CR. The median duration of response was 11 months. Thirteen of 21 evaluable 'PCR-positive' patients (62%) became 'PCR-negative' in PB and/or BM samples 1 month after rituximab, although this did not correlate with clinical response. Treatment was generally well tolerated, although one patient developed Stevens-Johnson syndrome. Rituximab was shown to be active in FL, and in some cases PB and/or BM became PCR negative. Studies in combination with cytotoxic chemotherapy to increase the CR rate are warranted.
0007-1048
81-88
Foran, J.M.
4b469095-77d2-4c02-92ec-3d3751d4cbf0
Gupta, R. K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Popescu, R. A.
257e3d8b-d33d-4b2d-80cb-89545d3dbbf9
Goldstone, A. H.
8ce52bfc-d857-4592-97a3-79525672b39d
Sweetenham, J.W.
4ea41ea4-f6aa-43c2-bb4c-804832d980e5
Pettengell, R.
a434acab-a2dd-4d77-9ff6-dbc480f30f09
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Bessell, E.
eebe366e-ecef-4c0e-8a34-decb75f3230b
Hancock, B.
682176b1-8dce-4838-8fdb-dfb0b49114c7
Summers, K.
05646b22-8f86-44ef-ba11-c89d94278dd9
Hughes, J.
d6a276c8-a7e5-46d9-9b3a-e7be07d4ddfc
Rohatiner, A. Z.
dc96c66a-7408-47b8-8238-c7b7ec5b9738
Lister, T. A.
0de6a9a4-2fe0-41b0-8226-a10d28d31f4c
Foran, J.M.
4b469095-77d2-4c02-92ec-3d3751d4cbf0
Gupta, R. K.
de1cf9ad-f52f-450b-b03b-d8bf1f44b91a
Cunningham, D.
02b4fd3a-f452-4419-96a7-f98f609f098d
Popescu, R. A.
257e3d8b-d33d-4b2d-80cb-89545d3dbbf9
Goldstone, A. H.
8ce52bfc-d857-4592-97a3-79525672b39d
Sweetenham, J.W.
4ea41ea4-f6aa-43c2-bb4c-804832d980e5
Pettengell, R.
a434acab-a2dd-4d77-9ff6-dbc480f30f09
Johnson, Peter W.M.
3f6068ce-171e-4c2c-aca9-dc9b6a37413f
Bessell, E.
eebe366e-ecef-4c0e-8a34-decb75f3230b
Hancock, B.
682176b1-8dce-4838-8fdb-dfb0b49114c7
Summers, K.
05646b22-8f86-44ef-ba11-c89d94278dd9
Hughes, J.
d6a276c8-a7e5-46d9-9b3a-e7be07d4ddfc
Rohatiner, A. Z.
dc96c66a-7408-47b8-8238-c7b7ec5b9738
Lister, T. A.
0de6a9a4-2fe0-41b0-8226-a10d28d31f4c

Foran, J.M., Gupta, R. K., Cunningham, D., Popescu, R. A., Goldstone, A. H., Sweetenham, J.W., Pettengell, R., Johnson, Peter W.M., Bessell, E., Hancock, B., Summers, K., Hughes, J., Rohatiner, A. Z. and Lister, T. A. (2000) A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. British Journal of Haematology, 109 (1), 81-88.

Record type: Article

Abstract

Follicular lymphoma (FL) cells express CD20 and are associated in most cases with the t(14;18) chromosomal translocation. A multicentre study was undertaken between January 1997 and January 1998 to assess the complete response rate (CR) and overall response rate (RR) to rituximab, a chimaeric anti-CD20 monoclonal antibody. Seventy patients with previously treated FL received rituximab (375 mg/m2/week x4, by intravenous infusion). Restaging studies were performed 1 and 2 months after therapy. Molecular monitoring for the presence of cells harbouring the Bcl-2/JH gene rearrangement in the peripheral blood (PB) and bone marrow (BM) was performed before and after treatment using a two-step semi-nested polymerase chain reaction (PCR) assay. The overall RR was 32/70 (46%), being highest in patients who had received only one previous treatment (12/15, 80%). However, only two patients achieved a CR. The median duration of response was 11 months. Thirteen of 21 evaluable 'PCR-positive' patients (62%) became 'PCR-negative' in PB and/or BM samples 1 month after rituximab, although this did not correlate with clinical response. Treatment was generally well tolerated, although one patient developed Stevens-Johnson syndrome. Rituximab was shown to be active in FL, and in some cases PB and/or BM became PCR negative. Studies in combination with cytotoxic chemotherapy to increase the CR rate are warranted.

Full text not available from this repository.

More information

Published date: April 2000

Identifiers

Local EPrints ID: 157833
URI: http://eprints.soton.ac.uk/id/eprint/157833
ISSN: 0007-1048
PURE UUID: 59a2e1bb-408f-48f7-a422-b47274782811
ORCID for Peter W.M. Johnson: ORCID iD orcid.org/0000-0003-2306-4974

Catalogue record

Date deposited: 16 Jun 2010 13:52
Last modified: 10 Dec 2019 01:51

Export record

Contributors

Author: J.M. Foran
Author: R. K. Gupta
Author: D. Cunningham
Author: R. A. Popescu
Author: A. H. Goldstone
Author: J.W. Sweetenham
Author: R. Pettengell
Author: E. Bessell
Author: B. Hancock
Author: K. Summers
Author: J. Hughes
Author: A. Z. Rohatiner
Author: T. A. Lister

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×